Jefferies initiated coverage on Instil Bio with a new price target
$TIL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Jefferies initiated coverage of Instil Bio with a rating of Buy and set a new price target of $31.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/7/2025 | $11.00 → $52.00 | Hold → Buy | Jefferies |
| 1/7/2025 | $11.00 → $52.00 | Hold → Buy | Truist |
| 11/4/2024 | Mkt Perform | JMP Securities | |
| 4/12/2024 | $5.00 → $11.00 | Buy → Hold | Jefferies |
| 11/1/2022 | $16.00 → $6.00 | Buy → Hold | Truist |
| 11/1/2022 | Outperform → Market Perform | Cowen | |
| 8/13/2021 | $34.00 | Outperform | Robert W. Baird |
| 8/13/2021 | $34.00 | Outperform | Baird |
10-Q - Instil Bio, Inc. (0001789769) (Filer)
8-K - Instil Bio, Inc. (0001789769) (Filer)
SCHEDULE 13G/A - Instil Bio, Inc. (0001789769) (Subject)
Jefferies upgraded Instil Bio from Hold to Buy and set a new price target of $52.00 from $11.00 previously
Truist upgraded Instil Bio from Hold to Buy and set a new price target of $52.00 from $11.00 previously
JMP Securities initiated coverage of Instil Bio with a rating of Mkt Perform
4 - Instil Bio, Inc. (0001789769) (Issuer)
4 - Instil Bio, Inc. (0001789769) (Issuer)
4 - Instil Bio, Inc. (0001789769) (Issuer)
With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 ("‘2510") anticipated before the end of 2025 Updated ‘2510 monotherapy data in squamous-NSCLC to be presented at IASLC's 2025 World Conference on Lung Cancer (WCLC) by ImmuneOnco DALLAS, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its second quarter 2025 financial results and provided a corporate update. Recent Highlights: In June, announced the appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical OfficerIn July, announced the Investigational Ne
Partial responses observed in 80% of squamous NSCLC front-line patients and in 46% of non-squamous NSCLC front-line patients Safety profile supports further clinical development, with no dose-limiting toxicities observed in patients with front-line NSCLC ImmuneOnco expects to present updated safety and efficacy data at a future medical conference DALLAS and SHANGHAI, July 31, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (NASDAQ:TIL, "Instil")) noted that ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK) ("ImmuneOnco"), today announced preliminary safety and efficacy data from the Phase 2 open-label, multicenter study of IMM2510/AXN-2510 (‘2510) in combination with ch
US phase 1 trial of ‘2510 is expected to be initiated before the end of 2025 Anticipate ImmuneOnco sharing initial safety and efficacy results from phase 2 trial of ‘2510 + chemo in 1L NSCLC in the second half of 2025 DALLAS, July 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced the clearance of an Investigational New Drug (IND) application for AXN-2510 ("'2510") by the U.S. Food and Drug Administration. Instil expects to initiate a phase 1 trial of ‘2510 as monotherapy for patients with relapsed/refractory solid tumors before the end of 2025. The trial i
SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)
SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)
SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)
With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 ("‘2510") anticipated before the end of 2025 Updated ‘2510 monotherapy data in squamous-NSCLC to be presented at IASLC's 2025 World Conference on Lung Cancer (WCLC) by ImmuneOnco DALLAS, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its second quarter 2025 financial results and provided a corporate update. Recent Highlights: In June, announced the appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical OfficerIn July, announced the Investigational Ne
DALLAS, June 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel cancer therapies, today announced the appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer. Dr. Freedman brings deep experience in oncology drug development and other therapeutic areas, and a track record of leading programs through all phases of development, regulatory approval and commercialization. Bronson Crouch, CEO of Instil, stated, "We are thrilled to welcome Dr. Freedman as Chief Medical Officer. Jamie's extensive experience and leadership in biopharmaceutical R&D will be a tremendous asset in adva
Manufacturing update on voluntary pause of DELTA-1 trial of ITIL-168 in advanced melanoma expected in Q1'23 Reprioritization of resources with enrollment deferred in DELTA-2 trial of ITIL-168 First patient with non-small cell lung cancer dosed with ITIL-306, the first engineered TIL therapy using CoStAR Platform, with plans to share clinical data in 2023 Appointment of cell therapy pioneer Dr. Robert Hawkins as Head of Research and Development, and resignation of Chief Medical Officer, Dr. Zachary Roberts Company confirms cash runway into 2025 with anticipated sale-leaseback transaction of its Tarzana manufacturing facility DALLAS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("